跳至主要内容
临床试验/IRCT20220827055798N1
IRCT20220827055798N1招募中3 期

The effect of combined regimen of ivermectin and fluoxetine on the prevention of hospitalization and amelioration of symptoms in mild covid-19 patients

Fasa University of Medical Sciences0 个研究点目标入组 144 人开始时间: 待定最近更新:

试验速览

阶段
3 期
状态
招募中
发起方
入组人数
144

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 65 years(—)
性别
All

入选标准

  • positive covid-19 PCR
  • Completion of the informed consent questionnaire

排除标准

  • Taking any SSRI for 10 days before the onset of clinical symptoms and going to the clinic
  • History of mental illnesses
  • Inability or unwillingness to continue studying
  • The need for oxygen therapy or a history of home oxygen therapy
  • History of chronic kidney and liver diseases
  • Use of warfarin, ACE inhibitor, angiotensin II receptor antagonists
  • Acquired immune system deficiency diseases
  • Pregnancy or breastfeeding9- Malnutrition diseases
  • Use of macrocyclic lactone drug family
  • Use of ivermectin for 7 days before the symptoms of covid-19
  • Participants who have participated in another trial study in the last six months.

研究者

发起方
Fasa University of Medical Sciences

相似试验